je.st
news
Tag: of
KEYTRUDA (pembrolizumab) Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express High Levels of PD-L1
2016-12-19 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA Also Approved for Second-Line Treatment of Patients with Advanced NSCLC Whose Tumors Express PD-L1 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, has been approved in Japan for the treatment of certain patients with PD-L1-positive unresectable advanced/recurrent non-small cell lung cancer (NSCLC) in the first- and second-line treatment settings at a fixed dose of 200 mg every three weeks. MSD will manufacture and market KEYTRUDA in Japan and will promote it with Taiho Pharmaceutical Co., Ltd. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Is He Serious? Shift Founders Mission is to be Worlds Largest Seller of Cars
2016-12-10 19:20:01| AutomotiveDigest.com - Automotive Industry News
Everyone is Approved: Sub Prime Auto Loan Strategy Under Siege by John Oliver, CFPB, Wall Street, and Growing Diligence of BHPH Dealers
2016-12-07 23:26:19| AutomotiveDigest.com - Automotive Industry News
Situation with Sub Prime Auto Lending: 86% of people get to work by car: A Must to hold down job; Over 25% of auto loans are high risk hence high interest rate 19% is average sub prime interest rate for up to 7 years 30% of subprime auto loans default so repo & re-loan cycle Significance of Where the Industry is & is going: Tired & aged used cars are sold & financed multiple times Industry has a Scam-Extraction Economy Image/Reputation Sub Prime Finance Bubble may be coming; Repeat of home loans BHPH dealers seize opportunity with less down & longer terms CFBP is seeking to police the sub prime market Reputable Sub Prime auto lenders & dealers seek to do it right Sit back & standby to watch a very entertaining, engaging, & timely video.
K&N Air Intake for 2015 & 2016 Ford F-150 Trucks Offers Estimated Boost of 12.7 Horsepower
2016-12-06 16:25:33| K&N Engineering, Inc. Air Filter, Air Intake, and other Product News
The K&N 63-2591 AirCharger Air Intake System dramatically reduces air intake restriction and permits the engine to grab more air than the factory air filter assembly allows.
KEYTRUDA (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology
2016-12-06 01:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Data from Pivotal KEYNOTE-087 Trial Show Overall Response Rate (ORR) of 69.0 Percent and Complete Remission Rate (CRR) of 22.4 Percent With More than Two Years of Follow-up, Findings from KEYNOTE-013 Show ORR of 58 Percent and CRR of 19 Percent with Responses of 12 Months or Greater in 70 Percent of Responding Patients KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today updated findings evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in two trials of patients with relapsed or refractory classical Hodgkin lymphoma (cHL). In the KEYNOTE-087 and KEYNOTE-013 trials, KEYTRUDA demonstrated overall response rates (ORR) of 69.0 percent and 58 percent, respectively. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: of
results
american
society
Sites : [275] [276] [277] [278] [279] [280] [281] [282] [283] [284] [285] [286] [287] [288] [289] [290] [291] [292] [293] [294] next »